<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119440</url>
  </required_header>
  <id_info>
    <org_study_id>CEPI-MVA-MERS-S-Phase1b</org_study_id>
    <nct_id>NCT04119440</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF-1</brief_title>
  <official_title>A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coalition for Epidemic Preparedness Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IDT Biologika Dessau.Rossau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CR2O</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a two center, randomized, double blind, placebo controlled study of the MVA
      MERS S_DF-1 candidate delivered by i.m. injection. To evaluate the MERS-S-specific antibody
      responses and safety profile induced by the two dosage levels of MVA-MERS-S_DF-1 the data
      will be compared to a placebo control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase Ib, two-center study in approximately 160 healthy adults aged 18-55
      years

      The study is separated in two parts:

      Part A:

      The study starts with a single center open-label run-in phase of two dose levels (cohort 1
      &quot;low dose&quot;: 2x10^7 PFU, cohort 2 &quot;high dose&quot;: 2x10^8 PFU) in 10 healthy subjects. 5 subjects
      will be allocated to each dose cohort and will receive immunization on day 0 and day 28.

      Part B:

      Two-center, randomized, double-blind, placebo-controlled, dose-finding study. This part is a
      double-blinded trial in approximately 150 healthy subjects. Subjects will be allocated to two
      different dose cohorts and a placebo cohort; each receiving three vaccine injections.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded with an open-label run-in Phase (Part A) Part A: Open-label Part B: Double-blind</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events associated with MVA-MERS-S_DF-1.</measure>
    <time_frame>day 1, 14, 29, 42, 56, 84, 168, 336, 364</time_frame>
    <description>Safety and reactogenicity will be assesssed by observation, questionaire and diary. Changes from baseline for safety laboratory measures will be monitored. Occurence of SAE will be collected throughout the entire study duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of local injection site reactogenicity signs and symptoms</measure>
    <time_frame>day 1, 14, 29, 42, 84, 336</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>day 0, 14, 28, 42, 56, 70, 84, 168, 336, 364 (dependent on vaccination scheme)</time_frame>
    <description>Magnitude of MERS-S-specific antibody re-sponses (ELISA and neutralization assays) monitored in a centralized approved laboratory</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>MERS (Middle East Respiratory Syndrome)</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-MERS-S_DF1 - Low Dose</intervention_name>
    <description>Administrations of the low dose via the intramuscular route</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-MERS-S_DF1 - High Dose</intervention_name>
    <description>Administrations of the high dose via the intramuscular route</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administrations of placebo via the intramuscular route</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent form.

          2. Healthy male and female subjects aged 18-55 years.

          3. No clinically significant acute health problems as determined from medical history and
             physical examination at screening visit.

          4. Body mass index 18.5 - 30.0 kg/m2 and weight &gt; 50 kg at screening.

          5. Non-pregnant, non-lactating female with negative pregnancy test.

          6. Males and females who agree to comply with the applicable contraceptive requirements
             of the protocol.

        Exclusion Criteria:

          1. Receipt of any vaccine from 2 weeks prior to each trial vac-cination (4 weeks for live
             vaccines) to 3 weeks after each trial vaccination.

          2. Receipt of vaccination against MERS or MVA immunizations.in the medical history.

          3. Known allergy to the components of the MVA-MERS-S_DF-1 vaccine product.

          4. Evidence in the subject's medical history or in the medical examination that might
             influence either the safety of the subject or the absorption, distribution, metabolism
             or excretion of the investigational product.

          5. Any confirmed or suspected immunosuppressive or immuno-deficient condition, cytotoxic
             therapy in the previous 5 years, and/or diabetes.

          6. Any chronic or active neurologic disorder, including seizures and epilepsy, excluding
             a single febrile seizure as a child.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marylyn M Addo, Prof</last_name>
    <phone>+49 40 7410 51102</phone>
    <email>m.addo@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric van Gorp, Prof</last_name>
    <phone>+31 10 7030310</phone>
    <email>e.vangorp@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CTC North</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Marylyn M Addo, Prof</last_name>
      <email>m.addo@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Alen Jambrecina, MD</last_name>
      <email>a.jambrecina@ctc-north.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric van Gorp, Prof</last_name>
      <email>e.vangorp@erasmusmc.ml</email>
    </contact>
    <contact_backup>
      <last_name>Matthijs Raadsen, MD</last_name>
      <email>m.p.raadsen@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 6, 2019</last_update_submitted>
  <last_update_submitted_qc>October 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MERS-CoV</keyword>
  <keyword>CEPI</keyword>
  <keyword>viral vector vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

